AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s stock had its “hold” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued on Monday. They presently have a $23.00 target price on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 25.34% from the stock’s previous close.
The analysts wrote, “AMAG disclosed that the Makena auto-injector sNDA has been accepted for review and that the FDA set a PDUFA date of February 14, 2018.””
A number of other research analysts have also weighed in on the stock. Barclays PLC reissued an “equal weight” rating and set a $20.00 price target (down from $25.00) on shares of AMAG Pharmaceuticals in a research report on Thursday, June 1st. ValuEngine lowered shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. TheStreet lowered shares of AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 5th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $34.00 price target (down from $40.00) on shares of AMAG Pharmaceuticals in a research report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the stock. AMAG Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $29.44.
Shares of AMAG Pharmaceuticals (NASDAQ AMAG) traded down 1.36% during midday trading on Monday, hitting $18.10. 400,305 shares of the stock were exchanged. The stock’s market capitalization is $634.31 million. AMAG Pharmaceuticals has a 1-year low of $16.00 and a 1-year high of $36.83. The firm’s 50 day moving average is $18.26 and its 200-day moving average is $23.88.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by $1.15. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The business had revenue of $139.47 million for the quarter, compared to analyst estimates of $150.32 million. During the same quarter in the prior year, the business earned ($0.22) earnings per share. The firm’s quarterly revenue was up 27.6% compared to the same quarter last year. On average, analysts predict that AMAG Pharmaceuticals will post $5.09 EPS for the current year.
In other AMAG Pharmaceuticals news, SVP Julie Krop sold 1,891 shares of AMAG Pharmaceuticals stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $24.45, for a total value of $46,234.95. Following the sale, the senior vice president now owns 36,777 shares of the company’s stock, valued at $899,197.65. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.80% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Teachers Advisors LLC raised its stake in shares of AMAG Pharmaceuticals by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 59,891 shares of the specialty pharmaceutical company’s stock valued at $2,084,000 after buying an additional 5,216 shares in the last quarter. Norges Bank bought a new stake in shares of AMAG Pharmaceuticals during the fourth quarter valued at approximately $19,914,000. Thrivent Financial for Lutherans raised its stake in shares of AMAG Pharmaceuticals by 5.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 18,380 shares of the specialty pharmaceutical company’s stock valued at $640,000 after buying an additional 1,000 shares in the last quarter. Guggenheim Capital LLC raised its stake in shares of AMAG Pharmaceuticals by 46.5% in the fourth quarter. Guggenheim Capital LLC now owns 126,556 shares of the specialty pharmaceutical company’s stock valued at $4,404,000 after buying an additional 40,149 shares in the last quarter. Finally, Seven Eight Capital LP bought a new stake in shares of AMAG Pharmaceuticals during the fourth quarter valued at approximately $212,000.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.